When 3D printing technology emerged, there was immediate excitement within the life science community, which quickly imagined the many possibilities. Fast forward to 2017 and 3D printing has expanded to “bioprinting,” or the practice of manufacturing tissue and organs with materials that incorporate viable living cells. This almost unbelievable technique has enabled practitioners to test advancements in the area of reconstructive surgery, transplantation and more.
We are pleased to announce our newest whitepaper which addresses this topic. Titled “3D Bioprinting – Printing for Life” and co-authored by our technology risk control specialists Tushar Nandwana and Steve Morkovsky, this reference piece defines bioprinting, discusses various current technologies and emerging applications, along with the associated risks and exposures.
To access of our full inventory of technology-focused whitepapers, visit our website.